Compare COLL & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | LGIH |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 984.3M |
| IPO Year | 2015 | 2013 |
| Metric | COLL | LGIH |
|---|---|---|
| Price | $34.50 | $41.25 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $50.83 | ★ $75.90 |
| AVG Volume (30 Days) | ★ 400.6K | 368.8K |
| Earning Date | 05-28-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.73 | ★ 3.12 |
| Revenue | $780,567,000.00 | ★ $1,705,504,000.00 |
| Revenue This Year | $6.07 | $6.01 |
| Revenue Next Year | N/A | $14.33 |
| P/E Ratio | $20.21 | ★ $13.16 |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $23.23 | $39.70 |
| 52 Week High | $50.79 | $74.84 |
| Indicator | COLL | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 16.51 | 25.66 |
| Support Level | $34.30 | N/A |
| Resistance Level | $36.20 | $55.90 |
| Average True Range (ATR) | 1.59 | 1.97 |
| MACD | -0.70 | -1.21 |
| Stochastic Oscillator | 2.18 | 10.11 |
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.